Diabetes MellitusNCT04976426
Establishment and Clinical Validation of a New Technique for Early Diagnosis of Diabetic Nephropathy
An observational study of Diabetes Mellitus and Biomarkers, run by Second Affiliated Hospital, Zhejiang University, School of Medicine.
Trial summary
Diabetic kidney disease(DKD) is a leading cause of chronic kidney disease and end-stage renal disease across the world. Early identification of DKD is vitally important for the effective prevention and control of it. However, the available indicators are doubtful in the early diagnosis of DKD. Read more about this study
- Who is it for?
- Ages 20 to 80 years
- Conditions the study is for
- Diabetes Mellitus, Biomarkers, Diabetic Kidney Disease
- How many people
- 1,000 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2022to 31 Dec 2026
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The diagnosis of T2DM in our study complied with the criteria set out by the American Diabetes Association. The inclusion criteria are as follows: for all patients diagnosed with T2DM without CKD. After five years of following up，participants were recruited and then divided into two groups: T2DM group without nephropathy(non-DKD, UACR urinary albumin/creatinine ratio < 3 mg/mmol) and DKD group with microalbuminuria and macroalbuminuria (DKD, UACR > 3 mg/mmol)
Who may be able to join
- Subjects who have signed informed consent.
- Subjects who were diagnosed with diabetes at least 5 years.
- Subjects showed good compliance, and the follow-up data was available for >5 years.
Who cannot join
- Renal diseases caused by other causes, including primary and secondary;
- All kinds of acute infections;
- The expected life expectancy (life expectancy or related diseases) was less than 5 years according to the researcher's judgment.
- Drug users or drug abusers;
- Sexually transmitted diseases such as viral hepatitis, AIDS and syphilis, and infectious diseases such as tuberculosis are in an active period;
- Any situation judged by the researcher that affects enrollment.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Diabetic kidney disease(DKD) is a leading cause of chronic kidney disease and end-stage renal disease across the world. Early identification of DKD is vitally important for the effective prevention and control of it. However, the available indicators are doubtful in the early diagnosis of DKD. This study aims to develop a novel system of multidimensional network biomarkers (MDNBs) to estimating early diabetic nephropathy, and further validating the performance of the novel systemin in prediction of the risk for early diabetic nephropathy by a nested case-control study.
Read the detailed description
Patients with a history of more than 5 years of diabetes without DKD were recruited. At the baseline visit, the patients' serum, plasma and urine were collected after obtaining informed patient consent. Simultaneously, the basic information, anthropometric indicators (including height, weight, waist circumference, hip circumference, blood pressure), past history, family history, menstrual history, birth history, medication history, lifestyle of the patients were registered, and the corresponding laboratory examination and auxiliary examination were carried out according to the diagnostic process. All data and data were entered into the database for later analysis. After 5years of follow up, subjects will be divided into two groups(the new onset DKD group and the non-DKD group), the base line level of MDNBs were tested in the two group to validate the performance of the novel MDNBs in in prediction of the risk for early diabetic nephropathy.
- Medical subject headings
- Diabetes Mellitus, Diabetic Nephropathies, Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
multidimensional network biomarkers
a novel system of multidimensional network biomarkers (MDNBs) based on a widely targeted metabolomics. Our previous study demonstrated that the combination of Linolelaidic Acid (C18:2N6T), L-Dihydroorotic Acid, and Azoxystrobin Acid might serve as a potential multidimensional network biomarkers of DKD. So we create a panel of MDNBs containing these biomakers as primary outcome measure.
Measured: 5years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jul 2021
- Study start1 Jan 2022 (estimated)
- Primary completion31 Dec 2023 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes MellitusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- Second Affiliated Hospital of Wenzhou Medical University, Lishui Country People's Hospital
- Responsible party
- Sponsor
- Investigators
- Zheng Chao, MD, PhD, Principal investigator, the Second Affiliated Hospital Zhejiang University Schoolof Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04976426
- Sponsor's protocol ID
- zhengchao3
- Status last verified
- Jun 2021
- First submitted
- 24 Jun 2021
- Last updated
- 26 Jul 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No